Liquid Array Protein Assay Platform

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI077249-01A1
Agency Tracking Number: AI077249
Amount: $99,999.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
ARRAYOMICS, INC., 9909 HIBERT ST, STE A, SAN DIEGO, CA, 92131
DUNS: 140695847
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 DAVID ROTHWARF
 (858) 245-2435
 DROTHWARF@ARRAYOMICS.COM
Business Contact
Phone: (858) 578-0977
Email: drothwarf@arrayomics.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The aim of this project is to extend application of a novel liquid array' platform, based on Encoded Sortable Particle (ESP) technology, into the protein assay realm. ESPs are optically-encoded microfabricated particle s that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the DNA space, to incorporate antibody-based protein detection assays in Phase I, and we will extend the scope o f protein assay coverage in Phase II. Phase I will consist of a 6-plex cytokine detection analysis, while Phase II is intended to accommodate assays of 1000-plex or more. In the protein space the ESP platform has significant advantages in cost, throughput, scalability, ease of use, and flexibility over existing bead-based liquid array and fixed array platforms. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease state s, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: ESP technology as applied to the protein assay space will provid e a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high-throughput discovery and clinical diagnostics. The ability to control the par ticles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflamm atory diseases, kidney disease, and infectious diseases (e.g. HIV).

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government